The French National Cancer Institute has introduced a competitive policy of labelling integrated cancer research sites (SiRIC). Their objective: to offer new operational conditions for translational research in cancerology, in order to optimize and accelerate the production of new knowledge and to promote its dissemination and application in the treatment of cancers.
SIRICs bring together, around the same site, medical services, multidisciplinary research teams (clinical, biological, technological, epidemiological, human, economic and social sciences and public health) and efficient common resources and services.
Together, these components should make it possible to carry out integrated multidisciplinary research programmes. This integration is defined by the sharing of research questions and objectives between the different disciplines, in order to jointly develop synergistic programmes, the aim of which is better cancer management.
The SIRICs thus have the following missions :
- to develop and conduct integrated research programmes;
- to set up programmes to disseminate knowledge and new practices.
Following a call for applications launched in April 2017, the Institute renewed the accreditation of six SIRICs and accredited two new SIRICs, including CURAMUS:
- SIRIC Curie : site de l’Institut Curie (Paris) ;
- LYriCAN (Manipulating cell plasticity for innovative cancer treatment) : site du centre Centre Léon Bérard (Lyon) ;
- BRIO (Bordeaux Recherche Intégrée Oncologie) : site de Bordeaux ;
- SIRIC Montpellier Cancer : site de Montpellier ;
- SOCRATE : site de l’Institut Gustave Roussy (Villejuif) ;
- CARPEM (CAncer Research for PErsonalized Medicine) : site de l’AP-HP regroupant les hôpitaux universitaires suivants : Hôpital Européen Georges Pompidou, Hôpital Cochin/Hôtel-Dieu et le département d’hématologie de l’hôpital Necker ;
- ILIAD (Imaging and Longitudinal Investigations to Ameliorate Decision Making) : site Nantes-Angers ;
- CURAMUS (Cancer United Research Associating Medicine, University & Society) : site du Groupe Hospitalier AP-HP.SORBONNE UNIVERSITÉ (Paris).
Funding for these SIRICs is provided jointly by an endowment from the Institut National du Cancer (INCa), the DGOS and Inserm on behalf of the Alliance for Life Sciences and Health (Aviesan).